Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma.
Naiki T, Nagai T, Sugiyama Y, Etani T, Nozaki S, Iida K, Noda Y, Shimizu N, Isobe T, Matsumoto D, Kubota H, Hamamoto S, Ando R, Kawai N, Yasui T. Naiki T, et al. Among authors: isobe t. Oncology. 2021;99(10):622-631. doi: 10.1159/000517326. Epub 2021 Jul 20. Oncology. 2021. PMID: 34284409
Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
Isobe T, Naiki T, Sugiyama Y, Naiki-Ito A, Nagai T, Etani T, Nozaki S, Iida K, Noda Y, Shimizu N, Tomiyama N, Banno R, Kubota H, Hamamoto S, Ando R, Kawai N, Yasui T. Isobe T, et al. Int J Clin Oncol. 2022 Jan;27(1):165-174. doi: 10.1007/s10147-021-02046-z. Epub 2021 Oct 11. Int J Clin Oncol. 2022. PMID: 34633579
A Multicenter, Prospective, Non-randomized Study Evaluating Surgical hand Preparation between Double-Gloving and Single-Gloving for Preventing Postoperative Infection in Robotic and Laparoscopic Minimally Invasive Surgeries.
Nagai T, Taguchi K, Isobe T, Matsuyama N, Hattori T, Unno R, Kato T, Etani T, Hamakawa T, Fujii Y, Ikegami Y, Kamiya H, Hamamoto S, Nakane A, Ando R, Maruyama T, Okada A, Kawai N, Yasui T. Nagai T, et al. Among authors: isobe t. Urol J. 2023 Feb 27;20(2):109-115. doi: 10.22037/uj.v19i.7239. Urol J. 2023. PMID: 36127829 Free article.
Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma.
Iida K, Naiki T, Etani T, Nagai T, Sugiyama Y, Isobe T, Aoki M, Nozaki S, Noda Y, Shimizu N, Tomiyama N, Gonda M, Kamiya H, Kubota H, Nakane A, Ando R, Kawai N, Yasui T. Iida K, et al. Among authors: isobe t. Sci Rep. 2024 Jan 30;14(1):2520. doi: 10.1038/s41598-024-53158-1. Sci Rep. 2024. PMID: 38291115 Free PMC article.
C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study.
Morikawa T, Naiki T, Sugiyama Y, Naiki-Ito A, Nagai T, Etani T, Iida K, Isobe T, Noda Y, Shimizu N, Aoki M, Gonda M, Banno R, Kubota H, Ando R, Umemoto Y, Kawai N, Yasui T. Morikawa T, et al. Among authors: isobe t. Cancers (Basel). 2024 Apr 28;16(9):1725. doi: 10.3390/cancers16091725. Cancers (Basel). 2024. PMID: 38730675 Free PMC article.
1,286 results